371 related articles for article (PubMed ID: 15197495)
1. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression.
Ahmad M; Rees RC; Ali SA
Cancer Immunol Immunother; 2004 Oct; 53(10):844-54. PubMed ID: 15197495
[TBL] [Abstract][Full Text] [Related]
2. Natural selection of tumor variants in the generation of "tumor escape" phenotypes.
Khong HT; Restifo NP
Nat Immunol; 2002 Nov; 3(11):999-1005. PubMed ID: 12407407
[TBL] [Abstract][Full Text] [Related]
3. Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape?
Malmberg KJ
Cancer Immunol Immunother; 2004 Oct; 53(10):879-92. PubMed ID: 15338206
[TBL] [Abstract][Full Text] [Related]
4. T-cell death and cancer immune tolerance.
Lu B; Finn OJ
Cell Death Differ; 2008 Jan; 15(1):70-9. PubMed ID: 18007660
[TBL] [Abstract][Full Text] [Related]
5. CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape.
Liu K; Caldwell SA; Greeneltch KM; Yang D; Abrams SI
J Immunol; 2006 Mar; 176(6):3374-82. PubMed ID: 16517705
[TBL] [Abstract][Full Text] [Related]
6. Strategies of tumor immune evasion.
Seliger B
BioDrugs; 2005; 19(6):347-54. PubMed ID: 16392887
[TBL] [Abstract][Full Text] [Related]
7. Tumor-host immune interactions and dendritic cell dysfunction.
Yang L; Carbone DP
Adv Cancer Res; 2004; 92():13-27. PubMed ID: 15530555
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell biology and its role in tumor immunotherapy.
Wang Y; Xiang Y; Xin VW; Wang XW; Peng XC; Liu XQ; Wang D; Li N; Cheng JT; Lyv YN; Cui SZ; Ma Z; Zhang Q; Xin HW
J Hematol Oncol; 2020 Aug; 13(1):107. PubMed ID: 32746880
[TBL] [Abstract][Full Text] [Related]
9. Newly emerged immunogenic neoantigens in established tumors enable hosts to regain immunosurveillance in a T-cell-dependent manner.
Muramatsu T; Noguchi T; Sugiyama D; Kanada Y; Fujimaki K; Ito S; Gotoh M; Nishikawa H
Int Immunol; 2021 Jan; 33(1):39-48. PubMed ID: 32729901
[TBL] [Abstract][Full Text] [Related]
10. Targeting unique tumor antigens and modulating the cytokine environment may improve immunotherapy for tumors with immune escape mechanisms.
Slingluff CL
Cancer Immunol Immunother; 1999 Oct; 48(7):371-3. PubMed ID: 10501849
[TBL] [Abstract][Full Text] [Related]
11. Strategies for immunotherapy of cancer.
Melief CJ; Toes RE; Medema JP; van der Burg SH; Ossendorp F; Offringa R
Adv Immunol; 2000; 75():235-82. PubMed ID: 10879286
[No Abstract] [Full Text] [Related]
12. [Immune system and tumors].
Terme M; Tanchot C
Ann Pathol; 2017 Feb; 37(1):11-17. PubMed ID: 28159405
[TBL] [Abstract][Full Text] [Related]
13. [Antitumor immunity and cellular cancer therapies].
Catros-Quemener V; Bouet F; Genetet N
Med Sci (Paris); 2003 Jan; 19(1):43-53. PubMed ID: 12836191
[TBL] [Abstract][Full Text] [Related]
14. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
[TBL] [Abstract][Full Text] [Related]
15. Immune responses to malignancies.
Whiteside TL
J Allergy Clin Immunol; 2010 Feb; 125(2 Suppl 2):S272-83. PubMed ID: 20061007
[TBL] [Abstract][Full Text] [Related]
16. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
Cancel JC; Crozat K; Dalod M; Mattiuz R
Front Immunol; 2019; 10():9. PubMed ID: 30809220
[TBL] [Abstract][Full Text] [Related]
17. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape.
Algarra I; García-Lora A; Cabrera T; Ruiz-Cabello F; Garrido F
Cancer Immunol Immunother; 2004 Oct; 53(10):904-10. PubMed ID: 15069585
[TBL] [Abstract][Full Text] [Related]
18. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R; Egle A; Villunger A
Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
[TBL] [Abstract][Full Text] [Related]
19. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.
Marincola FM; Jaffee EM; Hicklin DJ; Ferrone S
Adv Immunol; 2000; 74():181-273. PubMed ID: 10605607
[No Abstract] [Full Text] [Related]
20. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
Maccalli C; Parmiani G; Ferrone S
Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
